Literature DB >> 22584761

Treatment limitations at admission to intensive care units in Australia and New Zealand: prevalence, outcomes, and resource use*.

George Godfrey1, David Pilcher, Andrew Hilton, Michael Bailey, Carol L Hodgson, Rinaldo Bellomo.   

Abstract

BACKGROUND: Previous studies have addressed patients in whom treatment is withheld or withdrawn after a period of intensive care unit management. However, no studies have investigated the epidemiology of patients with treatment limitations in place at the time of intensive care unit admission.
OBJECTIVE: To report the epidemiology and outcome of patients with treatment limitations at intensive care unit admission and to identify characteristics associated with survival and discharge to home.
DESIGN: Retrospective database study using data from the Australian and New Zealand Intensive Care Society Adult Patient Database.
SETTING: Australian and New Zealand intensive care units. PATIENTS: One hundred eighty-seven thousand four hundred and one intensive care patients collected over a 3-yr period, 5,989 (3.2%) of whom had treatment limitations at admission to the intensive care unit.
INTERVENTIONS: Retrospective database study with no interventions. Data collected included patient characteristics, length of stay, mortality, and discharge destination. Mean intensive care unit bed days were used as a surrogate for resource consumption.
MEASUREMENTS AND MAIN RESULTS: Between January 1, 2007, and December 31, 2009, 5,989 (3.2%) patients were reported to the Australia and New Zealand Intensive Care Society Adult Patient Database who had treatment limitation orders at admission to intensive care unit. Mortality was 53% (95% confidence interval 51.7%-54.3%) compared with 9% (95% confidence interval 8.9%-9.1%) in patients admitted for full active management (p ≤ .001). Overall, 30% of patients with treatment limitations were discharged directly to their homes. Intensive care unit bed day usage was similar between the two groups. Within the treatment limitation group, younger patients, those with less comorbid diseases, less acute physiological disturbance, and those admitted following elective surgery, were more likely to survive and be discharged home. Admission diagnosis was an important determinant of outcome with intracranial or subarachnoid hemorrhage predicting a extremely high mortality.
CONCLUSIONS: Patients with treatment limitations on intensive care unit admission comprise approximately 2,000 patients per year in Australia and New Zealand. Despite such limitations, almost half of these patients survive their hospital admission and a third return directly to their home.

Entities:  

Mesh:

Year:  2012        PMID: 22584761     DOI: 10.1097/CCM.0b013e31824ea045

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  9 in total

1.  Variability Among US Intensive Care Units in Managing the Care of Patients Admitted With Preexisting Limits on Life-Sustaining Therapies.

Authors:  Joanna L Hart; Michael O Harhay; Nicole B Gabler; Sarah J Ratcliffe; Caroline M Quill; Scott D Halpern
Journal:  JAMA Intern Med       Date:  2015-06       Impact factor: 21.873

2.  [Quality of dying processes after commencement of the German Living Will Act : Experiences of a surgical intensive care unit].

Authors:  S Strauss; D Kuppinger; W H Hartl
Journal:  Chirurg       Date:  2017-03       Impact factor: 0.955

3.  The prevalence of perceptions of mismatch between treatment intensity and achievable goals of care in the intensive care unit: a cross-sectional study.

Authors:  Matthew H Anstey; Edward Litton; Michelle L Trevenen; Kelly Thompson; Steve Webb; Ian Seppelt; Imogen A Mitchell
Journal:  Intensive Care Med       Date:  2019-02-06       Impact factor: 17.440

4.  [Inadequate ICU-admissions : A 12-month prospective cohort study at a German University Hospital].

Authors:  K Bangert; J Borch; S Ferahli; S A Braune; G de Heer; S Kluge
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-09-04       Impact factor: 0.840

5.  The Natural History of Changes in Preferences for Life-Sustaining Treatments and Implications for Inpatient Mortality in Younger and Older Hospitalized Adults.

Authors:  Yan S Kim; Gabriel J Escobar; Scott D Halpern; John D Greene; Patricia Kipnis; Vincent Liu
Journal:  J Am Geriatr Soc       Date:  2016-04-27       Impact factor: 5.562

6.  Creating pre-conditions for change in clinical practice: the influence of interactions between multiple contexts and human agency.

Authors:  Michelle Myall; Carl May; Alison Richardson; Sarah Bogle; Natasha Campling; Sally Dace; Susi Lund
Journal:  J Health Organ Manag       Date:  2020-10-27

7.  Admission to Intensive Care for Palliative Care or Potential Organ Donation: Demographics, Circumstances, Outcomes, and Resource Use.

Authors:  Andrew Melville; Gali Kolt; David Anderson; Joanna Mitropoulos; David Pilcher
Journal:  Crit Care Med       Date:  2017-10       Impact factor: 7.598

8.  Limitation of life support techniques at admission to the intensive care unit: a multicenter prospective cohort study.

Authors:  Olga Rubio; Anna Arnau; Sílvia Cano; Carles Subirà; Begoña Balerdi; María Eugenía Perea; Miguel Fernández-Vivas; María Barber; Noemí Llamas; Susana Altaba; Ana Prieto; Vicente Gómez; Mar Martin; Marta Paz; Belen Quesada; Valentí Español; Juan Carlos Montejo; José Manuel Gomez; Gloria Miro; Judith Xirgú; Ana Ortega; Pedro Rascado; Juan María Sánchez; Alfredo Marcos; Ana Tizon; Pablo Monedero; Elisabeth Zabala; Cristina Murcia; Ines Torrejon; Kenneth Planas; José Manuel Añon; Gonzalo Hernandez; María-Del-Mar Fernandez; Consuelo Guía; Vanesa Arauzo; José Miguel Perez; Rosa Catalan; Javier Gonzalez; Rosa Poyo; Roser Tomas; Iñaki Saralegui; Jordi Mancebo; Charles Sprung; Rafael Fernández
Journal:  J Intensive Care       Date:  2018-04-13

9.  Automated alert and activation of medical emergency team using early warning score.

Authors:  Soo Jin Na; Ryoung-Eun Ko; Myeong Gyun Ko; Kyeongman Jeon
Journal:  J Intensive Care       Date:  2021-12-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.